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Abstract
Orthodontists need to know the effectiveness, efficiency and predictability of treatment
approaches and methods, which can be learned only by carefully studying and evaluating
treatment outcomes. The best data for outcomes come from randomized clinical trials (RCTs), but
retrospective data can provide satisfactory evidence if the subjects were a well-defined patient
group, all the patients were accounted for, and the percentages of patients with various possible
outcomes are presented along with measures of the central tendency and variation. Meta-analysis
of multiple RCTs done in a similar way and systematic reviews of the literature can strengthen
clinically-useful evidence, but reviews that are too broadly based are more likely to blur than
clarify the information clinicians need. Reviews that are tightly focused on seeking the answer to
specific clinical questions and evaluating the quality of the evidence available to answer the
question are much more likely to provide clinically useful data.
An orthodontist, like all health care providers, wants to know three things about the
treatment he or she is providing: its
1. effectiveness (how well it works, i.e., how effective it is in dealing with the
patient’s problems, taking into account possible negative side effects),
2. efficiency (how cost-effective it is, with cost in its broader sense to include time
and effort for the provider and impact on the patient), and
3. predictability (the amount of variation in patient response).
These things can be learned in only one way, by carefully evaluating treatment outcomes.
The hierarchy of quality in the evidence for clinical outcomes in orthodontics is shown in
Figure 1.1 This is similar to but differs in two ways from the classic diagram promulgated by
the Cochrane Collaboration as the ideal hierarchy for biomedical studies.
First, not all orthodontic conditions can be evaluated with randomized clinical trials
(RCT’s), so retrospective studies of treatment outcomes are, and will continue to be,
important sources of the evidence that underlies our clinical treatment. Although prospective
studies without random assignment of patients are sometimes viewed as better than
retrospective studies, a well-conducted retrospective study can provide equally reliable
information. Some important questions are impossible to answer with RCT’s because of
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ethical considerations, with the limits of orthodontic camouflage versus orthognathic surgery
being the best example. It is unacceptable to randomly assign patients to surgery. Many
other questions that theoretically could be evaluated in RCT’s cannot be answered that way
because of the slow pace of orthodontic treatment and the long follow-up required to be sure
of the stability of treatment outcomes. It simply costs too much and takes too long,
especially when adequate evidence can be obtained from well-conducted retrospective
studies.
Second, although it is correct that meta-analysis, combining the data from well-done clinical
trials, can strengthen (or weaken) the conclusion from those studies, it is critically important
that the data were obtained in a comparable way. This becomes a bigger problem when a
“systematic review” of the literature looks beyond clinical trials and incorporates a large
number of retrospective reports on a broad topic in an attempt to define guidelines for a
broad range of clinical problems. Reviews of that type are more likely to blur than clarify
the evidence that clinicians need.
The purpose of this paper is to further illustrate the problems we currently have in evaluating
clinical outcome data, and discuss ways to strengthen the evidence from retrospective
studies and reduce confusion from overly-extensive reviews of the literature.
What Does It Take to Obtain Good Retrospective Data?
There are three key criteria for good retrospective (or prospective) data:
1. The subjects were a well-defined patient group, who were selected by pre-treatment
characteristics and received specific treatment—not, for example, all the Class II
patients treated during a defined time period with a variety of methods. This is a
place where the inadequacies of the Angle classification particularly have an effect.
There are, of course, multiple types of Class I, II and III malocclusion, and clear
conclusions require distinction by facial as well as dental types and consideration
of all three planes of space.
There are far too many bad examples in the orthodontic literature of misleading
conclusions due to poorly-selected or biased samples and/or an attempt to answer
too broad a question. A good example is a recent study to answer the appropriately
focused question, “Are skeletal changes and an improved growth pattern obtained
in growing patients treated with a combination of bionator and high pull
headgear?”. This combination has been considered the most effective form of
treatment for long face problems, despite weak evidence from case reports and
small samples. An evaluation of records of 24 consecutively-treated patients with
this combination were compared to records of untreated patients selected for
similar age, gender, vertical skeletal relationships and time intervals between
records. The conclusion was surprisingly strong but justified: no long-term skeletal
changes were obtained and “Our findings suggest that treatment with bionator and
high pull headgear is not recommended for growing patients with hyperdivergent
facial patterns when the goal is to decrease the vertical dimension of the face.”2
2. All the patients, not just the ones judged to represent a successful outcome, are
accounted for in the report. Even if care is taken to avoid bias in selecting patients
for study, it is almost impossible to find all the post-treatment and/or follow-up
records (radiographs, photographs, dental casts) for all the patients eligible for
inclusion because of their pretreatment characteristics. When that is the case, an
important question is whether the missing patients are systematically different from
the ones remaining in the sample. That must be considered and examined to the
extent that the data set allows. It is easy to check the age and gender distribution in
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the initial and follow-up sample to see if it changed, and often there are other
known characteristics of the missing patients that can be compared in the same
way.
3. The statistical design and methodology is appropriate. Sample size and the
distribution of treatment changes are critical variables. The larger the sample size,
the more precise the statistical evaluation can be. The sample size needed to detect
a difference can (and should) be calculated in advance. A general guideline for
orthodontic outcome studies is that the sample size should be at least 20-25 to have
a reasonable chance of detecting statistical significance for clinically relevant
changes. 30-40 usually is large enough. Rarely does the sample need to be more
than 50, because small changes detected in a large sample, even if statistically
significant, are likely to be insignificant clinically. It is important to keep in mind
that in groups of treated patients, a few individuals usually have most of the
variation—so statistics based on the normal distribution can be misleading and
should not be used without verifying the distribution within the sample. Non-
parametric statistics often are required.
It also is important to look at the way the data are presented. This should not be just a table
of mean ± std. deviation. A box plot that shows the central tendency, estimate of deviation
and range within the sample gives a far better perception of the variability within the sample
(Figure 2) and guards against the frequent assumption that a change like the mean of the
sample represents what should be expected from future patients. In the presence of variable
responses, what the clinician really needs to know is the chance of a significant or highly
significant improvement for a new patient of the same type who will receive the same
treatment. For clinicians, it can be very helpful to be able to say, to yourself and the patient
or parent, that this approach has been shown to have a [definite percentage] chance of
success (Figure 3).
Considerations in Evaluating Clinical Trial Outcomes
The same guidelines as those for retrospective studies, of course, also apply to RCTs, but are
built into the fabric of the RCT research design. The great advantage of a randomized
clinical trial is that confounding factors are equalized during the randomization process, and
that it allows the evaluation of influences on pre- and post-treatment differences that had not
even been identified before the study began. As long as something is normally distributed
within both groups, its effect can be calculated. That does not mean that all clinical trial
results truly represent reality. A <5% probability that the result is erroneous means that
about one in 20 such studies will be wrong, and multiple comparisons increase the chance of
error.
The best outcome data orthodontists have ever had, and perhaps the best data we are likely
to obtain, come from the three major trials of early (preadolescent) versus later (adolescent)
treatment of excessive overjet.3,4,5 The research plans for the three trials were not identical,
but they are close enough to allow comparison of the findings. All three trials reported the
same thing: a small but statistically significant difference in mean a-p growth between
children who had a phase of preadolescent treatment and controls who did not, which
disappeared during adolescent treatment for all these patients. About 75% of the patients
improved during early treatment, the other 25% did not, and cooperation did not account for
all the difference.
The RCT results have been widely challenged by clinicians who offer some version of “If
you had done it properly [my way], it would have worked” and “You’re denying treatment
to children who really need it”. The current Cochrane Review of orthodontic treatment is
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based on eight RCTs, including the three major ones discussed above, and concludes “The
evidence suggests that providing early orthodontic treatment for children with prominent
upper front teeth is no more effective than providing one course of orthodontic treatment
when the child is in early adolescence.”6 The chance that multiple similar trials all got it
wrong is not zero, but it is vanishingly small. It is now nearly ten years after the early Class
II outcomes were published, and their gradually increasing acceptance leads one to hope for
broad acceptance within the next decade.
That does not mean that we now know everything about the timing of Class II treatment.
The importance of evaluating all the salient characteristics of a patient’s problems has
already been noted, and we do not have extensive clinical trial data for treatment of
combined Class II and vertical problems. The recent retrospective data for long-face Class II
treatment already has been noted.2 Some short face Class II patients have an impinging
overbite and trauma to the palatal tissues, which may be a valid reason for early treatment (I
think it is)—but good data to document this simply do not exist.
What should a clinician do for a child with this problem? The answer has to be “Use your
best clinical judgment”, based on whatever evidence is available coupled with your own
clinical experience and that of your teachers. In a broad overview of clinical practice, many
treatment decisions must be made in the absence of good evidence. Perhaps a reasonable
guideline is that substituting a new and complex treatment method for an older and simpler
one, in the absence of compelling evidence, rarely is wise. The important consideration, of
course, is the cost-benefit ratio—and sometimes an unproven new method is chosen in
dogged pursuit of a level of perfection that may be more of a benefit for the orthodontist
than the patient.
Another way to look at what can be learned from the clinical trials is what you can find out
by asking specific clinically-focused questions. For example, should an orthodontist expect a
shorter treatment time and better result for a mild Class II, and the reverse for a severe Class
II? If that is correct, it probably would affect the choice of treatment method and estimates
of treatment time. The UNC clinical trial data indicate, surprisingly, that the severity of the
initial jaw discrepancy is not a predictor of either post-treatment occlusion or treatment time
(Figure 4). Although that has been published,3 it wasn’t highlighted in a paper that largely
focused on two phase vs. one phase treatment—and many clinicians still think that initial
severity is an important predictor of time and outcome. The existing clinical trial data can
and should be used to search for answers to other clinically-focused questions.
Meta-analyses and Systematic Reviews: Current Problems
Meta-analysis was introduced as a way of combining data from multiple similar randomized
clinical trials to obtain a more powerful analysis. As a way to strengthen the conclusions,
this is appropriate and valuable—if the clinical trials really were focused on answering the
same question or questions, as the orthodontic Class II trials were. Systematic analysis of the
literature (systematic review) is an extension of the meta-analysis idea beyond clinical trials,
and sometimes a systematic review is called meta-analysis. Whatever it is called, broadening
the review to include retrospective reports requires great care in selection of the studies so
that they really are similar—and considering retrospective reports as equal to clinical trials
rarely is warranted.
At present, some meta-analyses of orthodontic clinical trials, and many if not most
systematic reviews of the orthodontic literature, conclude only that the data are weak and
further study is needed. Particularly in systematic reviews, a major part of the weakness
often is a lack of specifically focused clinical questions and evaluation of the quality of the
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currently available data to answer those questions. Often there is more extensive information
about the review process than about what the findings might mean in clinical practice.
A recent systematic review of the effects of orthognathic surgery on the oropharyngeal
airway nicely illustrates these problems.7 Its primary goal was to evaluate the extent to
which orthognathic surgery (primarily mandibular setback) could predispose patients to
sleep apnea or assist in treating it (maxillary, mandibular and/or chin advancement). This
was to be judged by studies of the treatment effect on airway dimensions. An extensive (and
extensively described) search of publication data bases yielded 59 full articles that were
retrieved for review; of these, 22 were included in the study because they met quality criteria
based on the way the study was carried out and reported. So far, so good—but only 4 of the
22 studies had 3D data, and the airway is an irregularly shaped three-dimensional space that
is almost impossible to evaluate accurately from the 2D cephalometric radiographs used in
the other 18 studies. Further, the extent to which the shape of the airway in upright and alert
individuals reflects its dimensions during sleep in a prone position is not known, but it
would be remarkable if there were no differences. The conclusion: “Three-dimensional
studies are important in the near future, … as evidence is lacking on the volume changes
after orthognathic surgery.” That does not provide any clinically useful information, and
leaves one to wonder about the indirect approach to sleep apnea in the first place. To
evaluate the effect of orthognathic surgery on sleep apnea, it would make more sense to
observe patients in a sleep lab before and after surgery.
The review of the literature that Joondeph did in preparation for his Angle Lecture at the
2012 AAO meeting offers an interesting contrast to the “big picture” systematic review.8 He
focused on the transverse changes associated with various types of orthodontic and surgical
treatment, identified five alternative ways to correct a transverse discrepancy, and asked
specific questions related to the type of treatment. The full report has not yet been published,
but a few examples of specific clinically important questions, and equally specific answers,
illustrate the difference with this approach.
Clinically-focused question 1: “Does it matter if your maxillary expansion appliance is
attached to bone screws or banded teeth”? The answer from a recent clinical trial: “Both
expanders showed similar results, and dental expansion was greater than skeletal expansion
in both groups”.9 Question 2: “What is the relationship between transverse expansion in the
maxilla and arch perimeter increase?” The answer, from a retrospective study of 21
consecutive palatal expansion cases: “The average perimeter gain was 0.7 times the amount
of transverse gain across the maxillary molars, but varied between 0.5 and 0.8”.10 Question
3: “Does that ratio apply to mandibular transverse expansion (where there is no skeletal
component, just tooth movement)”? The answer, from a CT modeling study and therefore
derived quite indirectly: “Lateral expansion of the mandibular molars results in perimeter
gain of 0.3 times the amount of transverse increase”.11 Question 4: “Does transverse
expansion of the maxilla improve the amount of maxillary protraction with early facemask
therapy?” The answer, from both a clinical trial12 and a retrospective study13: “Changes
were the same when using facemask therapy with or without expansion.” A reasonable
conclusion would be that the answers from the two RCTs and the answer from the
consecutively treated patients are credible, and that the answer from only a simulation study
(the arch perimeter gain from mandibular molar expansion) is rather dubious without
clinical confirmation.
Note the difference from a more typical systematic review: the focus is on the specific
aspects of treatment and the quality of the evidence that is available to answer specific
questions, not on a broad evaluation of the quality of evidence more generally. Should
clinicians care exactly how many papers exist with transverse expansion as their topic, and
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how many would be considered worth reviewing on the basis of screening criteria? Not if all
that detail gets in the way of answering questions that would directly influence clinical
practice. Nevertheless, it must be kept in mind that expert opinion has been used in a report
of this type to select the best evidence from the entire body of literature that deals with the
topic.
Conclusions
It is unfortunate that even evidence from multiple RCTs, as for two-phase versus one-phase
Class II treatment, still takes so long to really influence clinical practice. RCT data now exist
for the effect of maxillary expansion on protraction—simultaneous expansion does not
increase protraction12—but this has yet to decrease enthusiasm for combining the two
procedures, whether or not expansion is needed. Perhaps more clinically-focused
presentations of the available evidence and consideration of its quality in direct relationship
to answering clinical questions can facilitate the transition to evidence-based practice.
There is a long history in orthodontics of new ideas and methods that were adopted
enthusiastically and applied indiscriminately at first, well in advance of adequate evaluation.
As a result, within a decade the idea or method was largely discredited and discarded—so
now it is rarely used even in the situations where it was eventually shown to be a significant
advance. Two examples are sectioning gingival fibers to improve stability after correcting
rotations and distraction osteogenesis as a way to correct jaw discrepancies. Both are
effective, efficient and predictable in the right circumstances but now are rarely used even
when they are indicated.
At present, enthusiastic and extensive reviews of the literature that really do not help
clinicians move toward evidence-based practice are common. This is not because the
method is bad, but because it does not provide clinically useful answers if the questions are
not clinically focused and if the scope of the review goes outside comparable studies. As we
work toward evidence-based treatment, the goal should be to ask the right specific questions
and obtain answers that do have clinical utility. Otherwise, the evidence-based approach
risks being discredited and discarded as so many other new ideas have been.
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The hierarchy of quality for evidence in decisions for orthodontic patients. This diagram
differs from the more frequently-used hierarchy of the Cochrane Collaboration in two ways:
(1) it shows a greater recognition of the importance of good retrospective (or non-random
prospective) data because randomized clinical trials frequently are impossible or impractical,
given the long duration of treatment and longer follow-up required to evaluate the outcomes,
and (2) questions the importance of systematic reviews of the literature that, in contrast to
well-conducted clinical trials, often are poorly focused and potentially misleading.
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Phase 1 changes in the UNC Class II RCT for overjet and overbite. A, Tabulated data with
mean changes, standard deviation and range. B, The same data shown as box plots.
Although the numbers for the variability within the sample are there in the table, the
variability is shown much more clearly in the plots. Reports often are written with the
implication that the mean outcome is what should be expected for future patients—which is
incorrect and misleading, as the box plot shows.
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UNC Class II RCT data for the percentages of children with types of outcomes. It is true that
phase 1 treatment produced a significantly different outcome from the controls—but equally
true and more important that the chance of a favorable outcome was about 75% for both
functional appliance and headgear treatment, and the chance of a highly favorable outcome
(the result usually presented in case reports) was much lower.
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The relationship between A, the initial PAR score (before any treatment) and the final PAR
score at the end of phase 2 treatment for all patients and B, total treatment time and initial
PAR score. The data (from the UNC clinical trial) show what many clinicians have observed
about treatment for Class II problems: what looks like a difficult case may respond well to
treatment, and what looks like an easy case may not respond well at all. Now we have
evidence to support that view.
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